Resistant Hypertension: The Fourth Agent for a Long-Haul Driver
A single patient, three antihypertensives in and still uncontrolled. The disagreement isn't about which fourth drug is best in general — it's about which one this particular kidney, and this particular job, can actually tolerate.
P.W., a 58-year-old man, has driven long-haul freight routes for the better part of thirty years — irregular sleep, gas-station meals, and a DOT medical certification his blood pressure has kept on a one-year renewal cycle rather than the standard two. He was diagnosed with hypertension twelve years ago, and it has never come easily under control: he is now on losartan 100 mg and amlodipine 10 mg, both at maximum dose, alongside chlorthalidone 25 mg daily, and his blood pressure is still running high — 156/96 in clinic today, and an average of 152/92 on the home log his wife has kept for the past two months, so this isn't a white-coat problem.
Pharmacy refill records and a pill count at his last visit both confirm he is actually taking all three drugs as prescribed — roughly half of apparent treatment resistance turns out to be a missed-dose problem rather than a real pharmacologic one, and his isn't. His potassium is 4.8 mEq/L and his estimated GFR has settled at 52 mL/min/1.73m² (creatinine 1.5) — mildly-to-moderately reduced kidney function that his hypertension has likely been causing for years rather than the reverse. An aldosterone-renin ratio and a renal artery duplex, both sent two months ago when three drugs first failed to control him, came back unremarkable — no adrenal or renovascular lesion sitting underneath this.
That leaves a patient uncontrolled on three drug classes including a diuretic, with adherence and secondary causes both excluded — apparent treatment-resistant hypertension, with the formal label still hanging on one unfinished condition, since the definition requires every agent at its maximally tolerated dose and his diuretic is not there yet. Each of the real options from here carries a cost that lands specifically on him. Spironolactone has the best trial evidence of any fourth-line agent in resistant hypertension, but his potassium is already at the upper edge of normal and his kidney function is reduced enough that adding a mineralocorticoid receptor antagonist could push him into clinically meaningful hyperkalemia before it turns up on a routine recheck. Clonidine sidesteps the renal and potassium problem entirely, but its sedation and the real risk of rebound hypertension on a missed dose are hard to justify in a man who needs a current DOT card to keep driving for a living — a missed pill on a long haul isn't a hypothetical for him. Increasing his diuretic is the option with the least new risk, but chlorthalidone's effect narrows as kidney function declines, and it does nothing to address the aldosterone-driven salt retention a mineralocorticoid receptor antagonist would target directly.
In clinic, deciding on drug four
Don't add spironolactone today. His potassium is already 4.8 and his eGFR is 52 — that's not a contraindication on paper, but it's not room to move fast in, either. Increase the chlorthalidone first. Thiazide-type diuretics still have meaningful effect down to roughly an eGFR of 30, so there's real room to push before it stops working, and pushing it does something a spironolactone trial doesn't: it wastes potassium rather than retaining it.
That's not just caution for its own sake — a higher diuretic dose plausibly lowers his potassium over the next couple of weeks, which would widen the safety margin for spironolactone rather than simply delaying it. Sequencing this way isn't the same as ruling spironolactone out.
I'd rather not make him wait two weeks at 152 over 92. PATHWAY-2 is about as strong as fourth-line antihypertensive evidence gets, and in practice I start spironolactone in patients with labs like his all the time, with a potassium recheck in a week — that's a manageable monitoring burden, not a reason to hold off. I'd add both today.
What I won't do is put him on clonidine. I've filled out his DOT paperwork before — a driver who gets pulled over drowsy, or spikes because he couldn't get to a pharmacy on a route, isn't a hypothetical for him. That one's off the table regardless of where the rest of this lands.
Increase the chlorthalidone today — that part isn't actually contested. The disagreement is only about whether spironolactone joins it now or waits for the recheck, and the two-week window isn't arbitrary: it's roughly how long a higher thiazide-type dose takes to reach its steady kaliuretic effect, so checking any sooner wouldn't tell us anything his current labs don't already show. The two extra weeks of elevated pressure aren't nothing, but an unmonitored rise into clinically meaningful hyperkalemia in a man who's already at the upper edge of normal is the harder thing to walk back. Clonidine stays off the list either way.
Agreed: chlorthalidone increased to 50 mg daily today, clonidine ruled out for good given his DOT certification, and a repeat basic metabolic panel in two weeks. He was also referred for a sleep study given his BMI and reported snoring — untreated obstructive sleep apnea is a common, often-missed contributor to genuinely resistant hypertension, and the referral runs alongside the drug changes rather than waiting on them.
Not agreed, and the reason the two-week recheck carries a real decision rather than a formality:
Spironolactone 25 mg daily is added then, with a further potassium check in another week — the sequencing both voices could accept.
Spironolactone is deferred again; the diuretic dose and the sleep study findings are reassessed before it's revisited.
Nephrology and primary care left the room holding different views of what those two weeks cost him. Nobody set a compromise dose to split the difference; the pharmacologist set a concrete decision point instead — one recheck, two possible next steps, no drug added on today's labs alone.